Interestingly, individuals with familiar hypercholesterolemia—a strong genetic predisposition to atherosclerosis—were found to have a 3-fold higher CCR2 expression on classical monocytes than healthy subjects, whereas cholesterol lowering therapy with a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody reduced monocyte CCR2 surface expression by 60% in these patients (183). The gene discussed is CCR2; the disease is Hypercholesterolemia.